<DOC>
	<DOCNO>NCT01883869</DOCNO>
	<brief_summary>The hypothesis test ticagrelor ( Brilinta™ ) reduce platelet activation marker inflammation patient pneumonia .</brief_summary>
	<brief_title>Targeting Platelet-Leukocyte Aggregates Pneumonia With Ticagrelor</brief_title>
	<detailed_description>While well establish platelet integral hemostasis , recent evidence point important role platelet inflammation immunity . Platelet activation sequestration pulmonary tissue key feature inflammatory infectious state sepsis acute respiratory distress syndrome ( ARDS ) . Platelets may mediate acute lung injury ( ALI ) recruiting neutrophil , trigger neutrophil extracellular DNA net , release granule content microparticles . Anti-platelet therapy setting may prevent platelet activation , platelet - leukocyte aggregate formation , inflammation . The objective pilot study determine ticagrelor therapy individual pneumonia reduces marker platelet activation , platelet-leukocyte aggregate , inflammation , acute lung injury , lung mechanic . Because benefit anti-platelet therapy may greatest patient significant lung injury , investigator enroll patient community-acquired pneumonia ( CAP ) require hospitalization patient hospital acquire pneumonia ( HAP ) within 48 hour diagnosis . On study day 1 , subject randomize receive ticagrelor ( 180 mg load 90 mg BID ) placebo . Study medication ( ticagrelor placebo ) administer twice daily day 2 - 7 hospital discharge , sooner 7 day . Blood collect assay perform day 1 prior study medication administration ( baseline ) , day 2 , 3 , 7 , day discharge ( 7 day ) , 30 day analysis platelet count , marker platelet activation , platelet - leukocyte interaction , biomarkers inflammation , measurement lung mechanic .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Acute Lung Injury</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Adult</mesh_term>
	<mesh_term>Lung Injury</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Subjects must 18 year age old Subjects must diagnose Community acquire pneumonia ( CAP ) hospital acquire pneumonia ( HAP ) within 48 hour diagnosis presentation hospital . Pneumonia define patient new radiographic finding ( ) consistent pneumonia least two follow sign . 1 . Cough 2 . Fever : axillary temperature &gt; 37.5ºC tympanic temperature &gt; 38.5ºC 3 . Hypothermia : axillary temperature &lt; 34ºC tympanic temperature &lt; 35ºC . 4 . Purulent sputum production respiratory secretion . 5 . Total peripheral white blood cell ( WBC ) count &gt; 10,000/mm3 ; &gt; 15 % band form , regardless total peripheral white count ; leucopenia total WBC &lt; 4500/mm 6 . Auscultatory finding pulmonary examination rale and/or evidence pulmonary consolidation ( dullness percussion , bronchial breath sound , egophony ) 7 . Hypoxemia define partial O2 pressure &lt; 60mmHg patient breathe normal air decrease partial O2 pressure &gt; = 25 % initial range . 1 . Contraindication ticagrelor ( hypersensitivity reaction ticagrelor another P2Y12 antagonist ) 2 . Active bleeding major bleed history ( e.g . intracranial bleeding ) 3 . Clinically important anemia thrombocytopenia ( platelet count &lt; 30 ) 4 . Surgery within 30 day anticipate major surgery ( Thoracic , Abdominal , Brain ; placement line , tracheostomy , chest tube consider major ) . 5 . Oral anticoagulant therapy stop . 6 . Inability unwillingness treat physician reduce dose aspirin 81mg . 7 . Fibrinolytic therapy last 24 hour . 8 . Increased risk bradycardic event 2nd 3rd degree heart block , bradycardia induce syncope unless pacemaker place . 9 . Underlying immunodeficiency ( HIV , neutropenia , receive immunomodulating agent , active hematologic malignancy , functional anatomical asplenia hypogammaglobulinemia ) . 10 . Moderate severe liver disease define Child Pugh score &gt; 7 use data outpatient set alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 5 fold upper limit normal . 11 . Renal dialysis 12 . Concomitant therapy strong CYP3A inhibitor ; ketoconazole , itraconazole , voriconazole , saquinavir , nelfinavir , indinavir , atazanavir . 13 . Concomitant therapy CYP3A substate narrow therapeutic window : cyclosporin , quinidine . 14 . Concomitant therapy CYP3A inducer ; rifampin/rifampicin , phenytoin , carbamazepine . 15 . Pregnancy lactation 16 . Active treatment cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Platelet inhibition</keyword>
	<keyword>Platelet-leukocyte aggregate</keyword>
	<keyword>Platelet-neutrophil aggregate</keyword>
	<keyword>CAP</keyword>
	<keyword>HAP</keyword>
	<keyword>ALI</keyword>
	<keyword>Blood Platelets</keyword>
</DOC>